PriceTargets.com logo

Ampio Pharmaceuticals - AMPE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.25 As of 04/18/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AMPE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ampio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMPE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMPE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ampio Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.25.

This chart shows the closing price for AMPE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Ampio Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2022Alliance Global PartnersLower Target$90.00 ➝ $60.00N/A
3/24/2022Alliance Global PartnersInitiated CoverageBuy$90.00N/A
1/22/2021Roth CapitalReiterated RatingBuy$80.00N/A
12/19/2019Roth CapitalInitiated CoverageBuy$80.00N/A
12/18/2019Roth CapitalReiterated RatingBuyLow
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Ampio Pharmaceuticals logo
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Read More

Today's Range

Now: $0.25
Low: $0.22
High: $0.27

50 Day Range

MA: $1.35
Low: $0.24
High: $2.30

52 Week Range

Now: $0.25
Low: $0.14
High: $8.30

Volume

46,877 shs

Average Volume

153,591 shs

Market Capitalization

$285 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Ampio Pharmaceuticals?

The following equities research analysts have issued reports on Ampio Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for AMPE.

What is the current price target for Ampio Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Ampio Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ampio Pharmaceuticals in the next year.
View the latest price targets for AMPE.

What is the current consensus analyst rating for Ampio Pharmaceuticals?

Ampio Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMPE.

What other companies compete with Ampio Pharmaceuticals?

Other companies that are similar to Ampio Pharmaceuticals include Evofem Biosciences, Evelo Biosciences, Aditxt, Neptune Wellness Solutions and Galmed Pharmaceuticals. Learn More about companies similar to Ampio Pharmaceuticals.

How do I contact Ampio Pharmaceuticals' investor relations team?

Ampio Pharmaceuticals' physical mailing address is 373 Inverness Parkway, Suite 200, Englewood, CO 80112, United States. The company's listed phone number is 720-437-6500 and its investor relations email address is [email protected]. The official website for Ampio Pharmaceuticals is ampiopharma.com. Learn More about contacing Ampio Pharmaceuticals investor relations.